ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Articles tagged "Immunosuppression"

  • 2022 American Transplant Congress

    External Validation of the Abbreviated Ibox Scoring System at One-Year Post Kidney Transplant as a Surrogate Endpoint for Death-Censored Graft Survival

    A. Klein1, L. Kosinski2, R. Muse2, A. Loupy3, O. Aubert3, G. Divard3, M. Stegall4, I. Helanterä5, W. E. Fitzsimmons1, I. O'Doherty1

    1Transplant Therapeutics Consortium, Critical Path Institute, Tucson, AZ, 2Critical Path Institute, Tucson, AZ, 3Paris Transplant Group, Paris, France, 4Mayo Clinic, Rochester, MN, 5Helsinki University Hospital, Helsinki, Finland

    *Purpose: The Transplant Therapeutics Consortium seeks to translate the iBox from Loupy et al., 2019 into a surrogate endpoint for five-year death-censored graft survival after…
  • 2022 American Transplant Congress

    Low Fixed Tacrolimus Starting Dose and the Correlation with Renal Allograft Rejection

    R. Davoudi, E. Kitchel, S. Lee, T. Tan, T. Sievers, S. Bunnapradist

    David Geffen School of Medicine, Los Angeles, CA

    *Purpose: Achieving a tacrolimus therapeutic trough concentration (C0) by post-operative day (POD) 3-7 has been associated with a reduced risk for rejection. Although FDA prescribing…
  • 2022 American Transplant Congress

    Impact of Early Calcineurin-Inhibitor Conversion to Belatacept on Renal Allograft Function in a Steroid-Free Maintenance Regimen: Results from a Randomized Controlled Study

    I. Tawhari1, P. Hallak1, S. Hartzell2, V. Mas3, P. Cravedi2, J. Leventhal1, J. Ansari1, L. Gallon1

    1Northwestern University, Chicago, IL, 2Mount Sinai, New York, NY, 3University of Maryland, Baltimore, MD

    *Purpose: Belatacept (Bela) was developed to minimize nephrotoxicity and cardiovascular risk associated with Calcineurin inhibitors (CNIs). Early steroid withdrawal (ESW) and simultaneous CNI avoidance (CNIA)…
  • 2022 American Transplant Congress

    Covid-19 Vaccination Response In Tacrolimus Treated Kidney Transplant Recipients With And Without Mycophenolate Mofetil: Follow-up Of A Randomized Controlled Trial

    Z. Al Fatly1, M. G. Betjes1, A. L. Messchendorp2, J. S. Sanders2, M. E. Reinders1, M. M. Kho1, A. E. de Weerd1

    1Department of Internal Medicine, Erasmus MC Transplant Institute University Medical Center, Rotterdam, Netherlands, 2Department of Internal Medicine, Groningen Medical Center, Groningen, Netherlands

    *Purpose: To investigate the effect of mycophenolate mofetil (MMF) on SARS-CoV-2 vaccination response in kidney transplant recipients using the standard immunosuppressive regimen of tacrolimus (TAC)…
  • 2022 American Transplant Congress

    A Single-Center’s Outcomes of Combined Heart-Liver Transplantation

    R. W. Lincoln1, K. Kalvakuri2, A. Guha2, A. Bhimaraj2, E. E. Suarez2, A. Saharia3, C. M. Mobley3, F. Amirkhosravi3, J. Krisl1

    1Pharmacy, Houston Methodist Hospital, Houston, TX, 2DeBakey Heart and Vascular Associates, Houston Methodist Hospital, Houston, TX, 3Surgery, Houston Methodist Hospital, Houston, TX

    *Purpose: The purpose of this study was to evaluate rejection outcomes in our combined heart-liver transplant (CHLT) recipients at 6 months.*Methods: This is a retrospective,…
  • 2022 American Transplant Congress

    SARS-CoV-2 Antibody Response by mRNA Vaccine Platform in Incrementally Immunosuppressed Patients

    J. Mitchell1, C. Connolly1, T. Chiang1, J. Alejo1, W. Werbel1, D. Segev1, A. Massie2

    1Johns Hopkins University, Baltimore, MD, 2Johns Hopkins School of Medicine, Baltimore, MD

    *Purpose: This study compares SARS-CoV-2 antibody responses between the two-dose mRNA-1273 and BNT162b2 vaccine series across groups of incrementally immunosuppressed patients.*Methods: Semiquantitative testing for antibodies…
  • 2022 American Transplant Congress

    Understanding The Modification Of Eplet Mismatch Risk By Immunosuppression Regimen

    A. Johnson1, X. Zhang1, L. Gragert2, C. Larsen1

    1Emory University School of Medicine, Atlanta, GA, 2Tulane University School of Medicine, New Orleans, LA

    *Purpose: Solid organ transplant donor-recipient eplet mismatch has been correlated with subsequent donor specific antibody (DSA) formation, antibody mediated rejection, and overall rejection rates. However,…
  • 2022 American Transplant Congress

    Standard Induction with Basiliximab versus no Induction in Low Immunological Risk Kidney Transplant Recipients: Study Protocol for a Randomized Controlled Trial

    A. Ajlan1, H. Aleid1, T. Ali1, H. Joharji1, Z. Alabdulkarim1, T. Aburiash1, K. Almeshari1, A. Nazmi1, Y. Shah1, E. Devol1, D. Alkortas1, D. Broering1, I. Alahmadi1, A. Ullah1, A. Alotaibi1, A. Aljedai2

    1KFSHRC, RIYADH, Saudi Arabia, 2MOH, RIYADH, Saudi Arabia

    *Purpose: To compare different induction therapeutic strategies with 2 doses of basiliximab vs. no induction in low immunologic risk kidney transplant recipients as per KFSHRC…
  • 2022 American Transplant Congress

    Impact of Belatacept on Clinical Outcomes in Lung Transplant Patients with Antibody-Mediated Rejection

    L. Zaffiri, R. Hallak, S. Leonard, M. Neely, A. Hulber, H. Berry, K. A. Young, J. M. Reynolds

    Duke University, Durham, NC

    *Purpose: Antibody-mediated rejection (AMR) is cause of significant morbidity and mortality in lung transplant recipients (LTRs). An optimal therapeutic regimen is still lacking. Recent evidence…
  • 2022 American Transplant Congress

    Induction of Tacrolimus Clearance by Steroids Varies by Cyp3a5 Genotype in Kidney Transplant Recipients: A Drug-Drug-Gene Interaction

    P. A. Jacobson1, A. Saqr1, M. Al-Kofahi1, D. P. Schladt2, W. Guan3, W. S. Oetting1, R. Mannon4, C. R. Dorr5, R. P. Remmel1, G. C. Onyeaghala6, B. Wu3, A. K. Israni7, A. Matas8

    1Univ of MN, College of Pharmacy, Minneapolis, MN, 2Hennepin Health Research Institute, Minneapolis, MN, 3Univ of MN, Biostatistics, Minneapolis, MN, 4Univ of Nebraska, Dept of Medicine, Omaha, NE, 5Hennepin Health Research Institute and Dept of Medicine, Minneapolis, MN, 6Hennepin Healthcare Research Institute, Minneapolis, MN, 7Hennepin Health Dept of Medicine and Univ of MN, Minneapolis, MN, 8University of MN, Dept of Surgery, Minneapolis, MN

    *Purpose: Tacrolimus (TAC) is the primary immunosuppressant used in organ transplantation. TAC is a substrate for CYP3A4/5. These enzymes are inhibited or induced by multiple…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 138
  • Next Page »

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2026 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences